Resources Repository
-
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Health/Medicine | Sub-Saharan Africa | Environmental Health | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Child/Nutrition | Social Determinants | Health Systems | Climate/Environment | Economics/Finance -
ArticlePublication 2013Public Finance of Rotavirus Vaccination in India and Ethiopia: Extended CEA
This study uses extended cost-effectiveness analysis (ECEA) to evaluate a hypothetical publicly financed program for …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. The authors measured program impact on: (1) averted rotavirus deaths; (2) reduction in household expenditures; (3) financial risk protection; and (4) distributional consequences across the country’s wealth strata. In India and Ethiopia, the program was predicted to decrease rotavirus deaths substantially, and effectively provide financial risk protection among the poor, while also reducing household…
Health/Medicine | Culture/Society | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Health Outcomes | Cost-Effectiveness Analysis | Child/Nutrition | Social Determinants | Economics/Finance | Asia & Pacific -
ArticlePublication 2024Hepatitis C Elimination in Rwanda: Progress, Feasibility, Economic Evaluation
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis …
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis C virus (HCV) and identifies strategies to achieve World Health Organization (WHO) elimination goals by 2030. Employing a microsimulation model spanning 2015 to 2050, the analysis assesses HCV epidemic trends, prevalence, mortality, and total care costs under various scenarios. Results show that between 2018 and 2022, over 7 million people were screened and 60,000 treated, projecting Rwanda's potential achievement of…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Microsimulation | Chronic Disease/Risk -
ArticlePublication 2008Cost-Effectiveness of Rapid Point-of-Care Prenatal Syphilis Screening in Sub-Saharan Africa
This paper investigates the cost-effectiveness of using rapid point-of-care tests for prenatal syphilis screening among …
This paper investigates the cost-effectiveness of using rapid point-of-care tests for prenatal syphilis screening among pregnant women in sub-Saharan Africa, a region with syphilis prevalence rates as high as 17%, and where traditional multi-test screening methods have been challenging to implement. Focusing on newly available rapid point-of-care screening tests, strategies differed by the initial test [rapid plasma reagin (RPR), immunochromographic strip (ICS)], need for confirmation with Treponema pallidum hemagglutination assay, and number of visits required.…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Costing Methods | Test Performance | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Clinical Care -
ArticlePublication 2022Modeling the Relative Risk of Incidence and Mortality of Select Vaccine-Preventable Diseases
Immunization is one of the most effective public health interventions, saving millions of lives every …
Immunization is one of the most effective public health interventions, saving millions of lives every year. Ethiopia has seen gradual improvements in immunization coverage and access to child health care services; however, inequalities in child mortality across wealth quintiles and regions remain persistent. This paper models the relative distributional incidence and mortality of four vaccine-preventable diseases (VPDs) (rotavirus diarrhea, human papillomavirus, measles, and pneumonia) by wealth quintile and geographic region in Ethiopia. The authors approach…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Evidence Synthesis | Social Determinants -
ArticlePublication 2022Re-Evaluating the Health Impact and Cost-Effectiveness of Tuberculosis Prevention for Modern ART Cohorts
TB preventive therapy (TPT) is widely accepted to be cost-effective for reducing TB incidence in …
TB preventive therapy (TPT) is widely accepted to be cost-effective for reducing TB incidence in HIV-infected individuals receiving antiretroviral therapy (ART). However, as individuals initiate ART earlier in the course of disease, TB incidence is lower, and it is unclear how ART cost-effectiveness has changed. This study assessed the cost-effectiveness of TPT in contemporary ART cohorts. The authors developed a microsimulation model of TB and HIV and parameterised it using data from a large HIV…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Microsimulation | Cost-Effectiveness Analysis | Global -
ArticlePublication 2022Hospitalization Costs for COVID-19 in Ethiopia: Empirical Data and Analysis from Addis Ababa's Largest Dedicated Treatment Center
This study examines the comprehensive costs of hospitalization for COVID-19 disease at Ekka Kotebe COVID-19 …
This study examines the comprehensive costs of hospitalization for COVID-19 disease at Ekka Kotebe COVID-19 treatment center in Addis Ababa, Ethiopia, the largest dedicated hospital for COVID-19 patient care in the country. Through retrospective collection and analysis of clinical and cost data from March to November 2020, including personnel time, drugs, medical supplies, and facility utilities, the study estimates the cost per treated COVID-19 episode stratified by disease severity. Over the study period, 2,543 COVID-19…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Costing Methods -
ArticlePublication 2022Child Health Inequity through Case Management of Under-Five Malaria in Nigeria: An ECEA
This study assesses the potential impact of subsidies covering the direct and indirect costs of …
This study assesses the potential impact of subsidies covering the direct and indirect costs of under-five malaria case management in Nigeria, utilizing an extended cost-effectiveness analysis (ECEA) and a decision tree model. Findings reveal that fully subsidizing medical, non-medical, and indirect costs could annually avert over 19,000 under-five deaths, 8,600 cases of catastrophic health expenditure (CHE), and US$187 million in out-of-pocket (OOP) spending. Per US$1 million invested, this translates to a significant reduction in under-five…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Policy/Regulation -
ArticlePublication 2020Economic Evaluation of HBV Birth Dose Vaccination
This article, published in Cost Effectiveness and Resource Allocation, examines the cost-effectiveness of a birth …
This article, published in Cost Effectiveness and Resource Allocation, examines the cost-effectiveness of a birth dose of HBV vaccine in a medical setting in Ethiopia. The authors construct a decision analytic model with a Markov process to estimate the costs and effects of a birth dose of HBV vaccine, compared with current practices in Ethiopia. Based on the cost-effectiveness findings, introducing a birth dose of HBV vaccine in Ethiopia would likely be highly cost-effective. Such…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Cost-Effectiveness Analysis | Health Systems